Jeff Gordon Treatment Room the Newest Pit Stop at the CBCC

Today the Children's Blood and Cancer Center at Dell Children's Hospital in Austin unveiled a new treatment room sponsored by one of the undisputed greatest NASCAR drivers of all time, Jeff Gordon.

Gordon's four NASCAR Cup Series championships and three Daytona 500 victories only scratch the surface of the man's accomplishments on the track. But the Northern California-born Gordon's impact off the track is steadily becoming just as impressive, having focused his philanthropic efforts towards pediatric cancer fifteen years ago. What began as a local effort near his home in North Carolina has grown to impact kids as far away as Rwanda.

"These kids fighting cancer are some of the greatest champions I will ever know," said Gordon, whose Jeff Gordon Children's Foundation has contributed over $14 million to support kids diagnosed with cancer and their families since 1999. "[With the treatment room] we wanted to create a space that was fun and exciting, and a reminder that their visit to the hospital was just a pit stop on the way to victory over cancer."

The huge graphic above dominates the room, depicting Gordon's No. 24 Axalta Chevrolet SS making a pit stop at the Kobalt 400 NASCAR Sprint Cup Series race at Las Vegas Motor Speedway in March. Designed by Red Eye Designs of Charlotte, N.C., the eye-popping graphic was funded by one of Gordon's primary sponsors, Axalta Coating Systems.

Here is Red Eye Designs' graphic in closer detail:

Sponsoring a treatment room comes with other costs, and for the Jeff Gordon treatment room, funds were raised by the Austin chapter of the JGCF Promise Circle. They were able to obtain a significant contribution from the Austin office of the CBRE Group Inc.

Among several very cool details, the room includes a framed Jeff Gordon racing jacket (the glass of which reflects the graphic well; a photographer might say too well):

The sponsorship of a treatment room at the CBCC runs for three years, at which time sponsors can re-up for another three years.

....

[All photo credits: Ross Bonander. To see and download many more photos from this event, please visit my smugmug page.]

This is the twelfth installment in my series on the Children's Blood and Cancer Center at Dell Children's Hospital in Austin, Texas. The prior eleven are listed below:

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap